<DOC>
	<DOCNO>NCT02127697</DOCNO>
	<brief_summary>The study ass efficacy , safety tolerability NVA237 compare placebo patient poorly control asthma 52 week treatment .</brief_summary>
	<brief_title>Study Efficacy Safety NVA237 Patients With Poorly Controlled Asthma</brief_title>
	<detailed_description>The study ass efficacy safety NVA237 compare placebo , addition background therapy LABA/ICS patient poorly control asthma .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Written informed consent must obtain assessment perform ; Male female adult patient age 18 &lt; 75 year ; Patients diagnosis asthma ( accord GINA 2012 ) period least 5 year prior screen ; The diagnosis asthma must make patient 40 ; Increase force expiratory volume 1 second ( FEV1 ) ≥ 12 % ≥ 200 mLs within 30 minute administration 400 µg salbutamol/360 µg albuterol ( equivalent dose ) ; Prebronchodilator FEV1 ≥ 50 ≤ 80 % predict normal value patient ; Patients qualify treatment ( accord GINA 2012 ) treat stable dose fix dose inhale corticosteriod ( ICS ) longacting β2 agonist ( LABA ) combination least 4 week prior screen . Patient must use total daily dose ICS ≥800 μg/day budesonide equivalent ; All patient must symptomatic mean ACQ5 score ≥ 1.5 Visit 101 Visit 102 ; A documented history one asthma exacerbation previous 12 month require either treatment additional increase dose systemic corticosteroid least 3 day , emergency room visit , hospital treatment , intubation Contraindicated treatment , history reactions/ hypersensitivity follow inhaled drug , drug similar class , component thereof : Muscarinic antagonist agent , sympathomimetic amine , lactose excipients study drug , long short act beta2 agonist , corticosteroid ; Women childbearing potential ; Resting QTcF ≥ 450 m ( male ) ≥ 460 m ( female ) Visit 101 ( assessed central reader ) Visit 102 ( assess investigator site ) ; Patients body mass index ( BMI ) 40 kg/m2 ; Patients clinically significant renal , cardiovascular ( limited unstable ischemic heart disease , NYHA Class III/IV leave ventricular failure , myocardial infarction , arrhythmia , neurological , endocrine , immunological , psychiatric , gastrointestinal , hepatic , hematological abnormality could interfere assessment efficacy safety study treatment ; Patients narrowangle glaucoma , symptomatic benign prostatic hyperplasia bladderneck obstruction moderate severe renal impairment urinary retention ( BPH patient stable treatment consider ) ; Patients asthma exacerbation require either treatment additional increase dose systemic corticosteroid least 3 day , emergency room visit , hospital treatment , intubation 6 week prior screen ; Patients smoke inhaled tobacco product within 6 month period prior screening , smoke history great 10 pack year ( Note:10 pack year = 1 pack /day x 10 yrs. , ½ pack/day x 20 yr . ) ; Patients history chronic lung disease asthma , include ( limited ) chronic obstructive pulmonary disease , bronchiectasis , sarcoidosis , interstitial lung disease , cystic fibrosis , tuberculosis ( unless tuberculosis confirm longer active imaging ) ; Patients Maintenance Immunotherapy ( desensitization ) allergies must least 3 month prior runin , must expect remain unchanged throughout course study ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Asthma , poorly control asthma , LAMA , Long-Acting Muscarinic Antagonist , Glycopyrronium , Glycopyrronium bromide , Anticholinergic</keyword>
</DOC>